What is mAb?

COVID-19 monoclonal antibodies (mAb) are treatments available to people who have tested positive for COVID-19, exhibit mild to moderate symptoms of the disease, and who are at high risk of developing severe COVID-19. When given in the first 10 days of illness, treatments can prevent hospitalizations and/or severe complications caused by COVID-19.


 

This project is funded by a grant from the National Institutes of Health (NIH) and National Center for Advancing Translational Sciences (NCATS) (award number UL1-TR002535-03S3).